本文選題：治療性抗體 + 抗體半衰期�。� 參考：《中國生物工程雜志》2017年05期

【摘要】：隨著治療性單克隆抗體在臨床治療方面發(fā)揮的作用日益突顯,其全球藥物市場所占份額和研發(fā)投入均在逐年增加。除了抗體新藥的開發(fā),抗體藥物效力和安全性相關(guān)的基因工程改造也越來越受到重視。在這些基因工程改造中,抗體半衰期改造已成為近年來研究的熱點之一。對幾種抗體半衰期改造技術(shù)進行了介紹,并簡要描述了半衰期改造后抗體的臨床研究現(xiàn)狀。
[Abstract]:With the increasing role of therapeutic monoclonal antibodies in clinical treatment, its global drug market share and R & D investment are increasing year by year. In addition to the development of new antibody drugs, more and more attention has been paid to the genetic engineering related to the efficacy and safety of antibody drugs. In these genetic engineering modifications, antibody half-life modification has become one of the hotspots in recent years. In this paper, several antibody half-life modification techniques are introduced, and the clinical research status of antibody after half-life modification is briefly described.
【作者單位】： 廈門大學(xué)國家傳染病診斷試劑與疫苗工程技術(shù)研究中心生命科學(xué)學(xué)院;廈門大學(xué)公共衛(wèi)生學(xué)院;
【基金】：國家自然科學(xué)基金資助項目(81401668,2017J01066,31600748)
【分類號】：R392
，

本文編號：1883528